Literature DB >> 9203027

Uveitis in Behçet's disease.

R B Nussenblatt1.   

Abstract

The ocular complications of Behçet's disease are considered one of the major criteria upon which the diagnosis is based. Its complications are frequently sight threatening and require constant attention. The ocular disease is characterized by repeated, explosive ocular inflammatory attacks which get better by themselves, so that in-between attacks there is little or no evidence of inflammatory disease in the eye. The anterior segment can be involved alone, most frequently presenting as a severe anterior uveitis, frequently with hypopyon. This is not associated with a poor visual outcome, and usually treated with topical medication to make the patient more comfortable. However, the anterior segment disease is usually accompanied by recurrent retinal vaso-occlusive disease which is sight threatening if repeated attacks occur. Treatment is with systemic medications, including corticosteroids, cyclosporine, FK506, anti-metabolites, and cytotoxic agents. Complications of the inflammation can include retinal and optic atrophy, vitreous hemorrhage, neovascular glaucoma, and retinal detachment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203027     DOI: 10.3109/08830189709116845

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  27 in total

1.  Evaluation of serum leptin concentration in Behçet's disease with ocular involvement.

Authors:  Sevim Kavuncu; Feray Koç; Melih Kurt; Buğra Eryüksel; Serap Ortaç; Pinar Ozdal; Esin Firat
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-05-20       Impact factor: 3.117

Review 2.  Behçet's disease: global epidemiology of an Old Silk Road disease.

Authors:  Hiroshi Keino; Annabelle A Okada
Journal:  Br J Ophthalmol       Date:  2007-12       Impact factor: 4.638

3.  Clinical course of patients with Behçet's uveitis following discontinuation of infliximab therapy.

Authors:  Tatsushi Kawaguchi; Yuko Kawazoe; Koju Kamoi; Masaru Miyanaga; Hiroshi Takase; Sunao Sugita; Manabu Mochizuki
Journal:  Jpn J Ophthalmol       Date:  2013-10-16       Impact factor: 2.447

Review 4.  Gene therapy in the treatment of ocular inflammation.

Authors:  K Csaky; R Nussenblatt
Journal:  Springer Semin Immunopathol       Date:  1999

Review 5.  Current approach in the diagnosis and management of panuveitis.

Authors:  Reema Bansal; Vishali Gupta; Amod Gupta
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

6.  Hypopyon in patients with uveitis.

Authors:  Ali A Zaidi; Gui-Shuang Ying; Ebenezer Daniel; Sapna Gangaputra; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; John H Kempen
Journal:  Ophthalmology       Date:  2009-12-14       Impact factor: 12.079

7.  Topographic optic disc analysis by Heidelberg retinal tomography in ocular Behcet's disease.

Authors:  Nilufer Berker; Ufuk Elgin; Pinar Ozdal; Aygen Batman; Emel Soykan; Seyhan S Ozkan
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

8.  Long-term therapy with low dose cyclosporin A in ocular Behçet's disease.

Authors:  Pinar Cakar Ozdal; Serap Ortaç; Ibrahim Taskintuna; Esin Firat
Journal:  Doc Ophthalmol       Date:  2002-11       Impact factor: 2.379

Review 9.  Pentoxifylline for the treatment of anterior uveitis in Behcet's disease: possible alternative for TNF blockers.

Authors:  Simone Appenzeller; Elizabeth Hazel
Journal:  Rheumatol Int       Date:  2009-12-16       Impact factor: 2.631

Review 10.  Headache in Behçet's syndrome: review of literature and NYU Behçet's syndrome center experience.

Authors:  Vijay Vishwanath; Ericka Wong; Sara C Crystal; Matthew S Robbins; Maria Filopoulos; Richard B Lipton; Yusuf Yazici; Ilya Kister
Journal:  Curr Pain Headache Rep       Date:  2014-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.